Abstract: The invention relates to certain low-molecular weight sulphated polysaccharide derivatives of marine native exopolysaccharides (EPSs) excreted by mesophilic marine bacteria from a deep hydrothermal environment, wherein said derivatives can be obtained by means of a method which comprises a step of free radical depolymerization of said native EPSs followed by a step of sulphating the resulting depolymerized derivatives. The present invention further relates to the use of said low-molecular weight sulphated polysaccharide derivatives as a wound-healing agent, particularly for preparing pharmaceutical compositions suitable for treating or preventing diseases of the connective tissues and particularly skin and gum tissues. The figure demonstrates how polysaccharide derivative GY 785 DRS according to the invention can stimulate fibroblast proliferation in latticed or reconstructed connective tissues at a concentration of 10 ?g (m) g/ml.

Abstract: The present invention relates to a biocidal composition including at least one active biocidal compound and at least one nonionic or anionic exopolysaccharide (EPS), the active biocidal compound being selected from at least one triamine having the following formula I, R1NR2R3, formula I where R1 is an aminoalkyl radical comprising a straight or branched chain having 2 to 16 carbon atoms, R2 is a hydrogen atom or a straight or branched alkyl chain having 1 to 18 carbon atoms, and R3 is, independently from R1, an aminoalkyl radical comprising a straight or branched chain having 2 to 16 carbon atoms or a —CH2—CH2—CH2—NH—R4 radical, where R4 is a saturated or unsaturated fatty acid chain including 4 to 20 carbon atoms or a mixture of C4-C20 alkyl chains, characterized in that the biocidal composition includes, by weight and relative to the total weight of said biocidal composition, 0.5 to 90% of the biocidal compound and 0.1 to 10% of the exopolysaccharide.

Abstract: The present invention relates to a biocidal composition including at least one active biocidal compound and at least one nonionic or anionic exopolysaccharide (EPS), the active biocidal compound being selected from at least one triamine having the following formula I, R1NR2R3, formula I where R1 is an aminoalkyl radical comprising a straight or branched chain having 2 to 16 carbon atoms, R2 is a hydrogen atom or a straight or branched alkyl chain having 1 to 18 carbon atoms, and R3 is, independently from R1, an aminoalkyl radical comprising a straight or branched chain having 2 to 16 carbon atoms or a —CH2—CH2—CH2—NH—R4 radical, where R4 is a saturated or unsaturated fatty acid chain including 4 to 20 carbon atoms or a mixture of C4-C20 alkyl chains, characterized in that the biocidal composition includes, by weight and relative to the total weight of said biocidal composition, 0.5 to 90% of the biocidal compound and 0.1 to 10% of the exopolysaccharide.

Abstract: The invention relates to certain low-molecular weight sulphated polysaccharide derivatives of marine native exopolysaccharides (EPSs) excreted by mesophilic marine bacteria from a deep hydrothermal environment, wherein said derivatives can be obtained by means of a method which comprises a step of free radical depolymerisation of said native EPSs followed by a step of sulphating the resulting depolymerised derivatives. The present invention further relates to the use of said low-molecular weight sulphated polysaccharide derivatives as a wound-healing agent, particularly for preparing pharmaceutical compositions suitable for treating or preventing diseases of the connective tissues and particularly skin and gum tissues. The figure demonstrates how polysaccharide derivative GY 785 DRS according to the invention can stimulate fibroblast proliferation in latticed or reconstructed connective tissues at a concentration of 10 ?g (m) g/ml.

Abstract: The invention relates to certain low-molecular weight sulphated polysaccharide derivatives of marine native exopolysaccharides (EPSs) excreted by mesophilic marine bacteria from a deep hydrothermal environment, wherein said derivatives can be obtained by means of a method which comprises a step of free radical depolymerization of said native EPSs followed by a step of sulphating the resulting depolymerized derivatives. The present invention further relates to the use of said low-molecular weight sulphated polysaccharide derivatives as a wound-healing agent, particularly for preparing pharmaceutical compositions suitable for treating or preventing diseases of the connective tissues and particularly skin and gum tissues. The figure demonstrates how polysaccharide derivative GY 785 DRS according to the invention can stimulate fibroblast proliferation in latticed or reconstructed connective tissues at a concentration of 10 ?g (m) g/ml.

Abstract: The invention relates to certain low-molecular weight sulphated polysaccharide derivatives of marine native exopolysaccharides (EPSs) excreted by mesophilic marine bacteria from a deep hydrothermal environment, wherein said derivatives can be obtained by means of a method which comprises a step of free radical depolymerisation of said native EPSs followed by a step of sulphating the resulting depolymerised derivatives. The present invention further relates to the use of said low-molecular weight sulphated polysaccharide derivatives as a wound-healing agent, particularly for preparing pharmaceutical compositions suitable for treating or preventing diseases of the connective tissues and particularly skin and gum tissues. The figure demonstrates how polysaccharide derivative GY 785 DRS according to the invention can stimulate fibroblast proliferation in latticed or reconstructed connective tissues at a concentration of 10 ?g (m) g/ml.

Abstract: The invention relates to certain low-molecular weight sulphated polysaccharide derivatives of marine native exopolysaccharides (EPSs) excreted by mesophilic marine bacteria from a deep hydrothermal environment, wherein said derivatives can be obtained by means of a method which comprises a step of free radical depolymerisation of said native EPSs followed by a step of sulphating the resulting depolymerised derivatives. The present invention further relates to the use of said low-molecular weight sulphated polysaccharide derivatives as a wound-healing agent, particularly for preparing pharmaceutical compositions suitable for treating or preventing diseases of the connective tissues and particularly skin and gum tissues. The figure demonstrates how polysaccharide derivative GY 785 DRS according to the invention can stimulate fibroblast proliferation in latticed or reconstructed connective tissues at a concentration of 10 ?g (m) g/ml.

Abstract: The present invention relates to a nucleus covered or coated with a film including one or more PHA. The invention also relates to a PHA, characterized in that it is of the type PHB-V, a film and a composition including the PHA. The invention further relates to a film or a composition including a PHA and zosteric acid or a bioactive molecule. The invention moreover relates to a surface, preferably a nucleus, covered with the film of PHA, a method for production thereof, and methods for grafting a pearl oyster and producing a pearl using this nucleus. Finally, the present invention relates to a method for reducing graft failure and/or for improving the quality of the pearl using the nucleus according to the invention.

Abstract: A nucleus coated with a film includes one or more exopolysaccharides (EPS) and optionally one or more bioactive molecules such as bactericidal or bacteriostatic agents, cicatrizing agents and/or anti-inflammatory agents. A method for obtaining the nucleus, in order to inhibit graft rejection in pearl oysters is also described.

Abstract: Exopolysaccharides, preferably obtained by fermenting bacteria from deep hydrothermal ecosystems, serve as agents for preventing the formation of unwanted biofilms on a surface. A method for protecting a surface by preventing the formation of the primary film leading to unwanted biofilms, includes placing the surface in contact with at least one exopolysaccharide, or grafting the exopolysaccharide onto the surface. A method for modifying the physical properties of a surface such that the adhesion of an unwanted bacterial biofilm to the surface is reduced is also described.

Abstract: The invention relates to the use of a polysaccharide which is excreted by the Vibrio diabolicus species for the regeneration and protection of the non-mineralised connective tissue of the periodontium.

Abstract: The invention relates to certain low-molecular weight sulphated polysaccharide derivatives of marine native exopolysaccharides (EPSs) excreted by mesophilic marine bacteria from a deep hydrothermal environment, wherein said derivatives can be obtained by means of a method which comprises a step of free radical depolymerisation of said native EPSs followed by a step of sulphating the resulting depolymerised derivatives. The present invention further relates to the use of said low-molecular weight sulphated polysaccharide derivatives as a wound-healing agent, particularly for preparing pharmaceutical compositions suitable for treating or preventing diseases of the connective tissues and particularly skin and gum tissues. The figure demonstrates how polysaccharide derivative GY 785 DRS according to the invention can stimulate fibroblast proliferation in latticed or reconstructed connective tissues at a concentration of 10 ?g (m) g/ml.

Abstract: The invention relates to the use of certain low-molecular weight highly sulphated polysaccharide derivatives obtained from a bacterial polysaccharide for preparing a pharmaceutical composition suitable for modulating angiogenesis, particularly for use in accelerating vascular endothelial repair with a low haemorrhage risk in the event of thrombotic injuries.

Abstract: The invention relates to the use of a polysaccharide which is excreted by the Vibrio diabolicus species for the re-generation and protection of the non-mineralised connective tissue of the periodontium.

Abstract: The invention relates to the use of a polysaccharide which is excreted by the Vibrio diabolicus species for the engineering of non-mineralised connective tissues, in particular for skin and cartilage engineering.

Abstract: An immunogenic conjugate includes a target cell-specific circulating molecule and at least one immunogenic agent, the immunogenic agent being coupled by any appropriate means with the circulating molecule. Also described is a method for preparing the immunogenic conjugate and its use for treating cancers or autoimmune diseases.

Abstract: The invention relates to certain low-molecular weight sulphated polysaccharide derivatives of marine native exopolysaccharides (EPSs) excreted by mesophilic marine bacteria from a deep hydrothermal environment, wherein said derivatives can be obtained by means of a method which comprises a step of free radical depolymerisation of said native EPSs followed by a step of sulphating the resulting depolymerised derivatives. The present invention further relates to the use of said low-molecular weight sulphated polysaccharide derivatives as a wound-healing agent, particularly for preparing pharmaceutical compositions suitable for treating or preventing diseases of the connective tissues and particularly skin and gum tissues. The figure demonstrates how polysaccharide derivative GY 785 DRS according to the invention can stimulate fibroblast proliferation in latticed or reconstructed connective tissues at a concentration of 10 ?g(m)g/ml.

Abstract: The invention relates to the use of certain low-molecular weight highly sulphated polysaccharide derivatives obtained from a bacterial polysaccharide for preparing a pharmaceutical composition suitable for modulating angiogenesis, particularly for use in accelerating vascular endothelial repair with a low haemorrhage risk in the event of thrombotic injuries.

Abstract: The invention concerns the use of a polysaccharide excreted by the Vibrio diabolicus species for making a medicine with cicatrising activity, in particular bone repair activity. The invention also concerns a bone reconstruction biomaterial comprising said polysaccharide and a bone endoprosthesis whereof the surface is coated with such a polysaccharide.

Abstract: The invention concerns the use of a polysaccharide excreted by the Vibrio diabolicus species for making a medicine with cicatrising activity, in particular bone repair activity. The invention also concerns a bone reconstruction biomaterial comprising said polysaccharide and a bone endoprosthesis whereof the surface is coated with such a polysaccharide.